Delcath Systems: Filtering Through Its Past & Future
An interview with Gerard Michel, CEO of Delcath Systems, where Gerard reflects back on his time with Vericel, the decision to become CEO of…
Coverage
Blog
Latest research notes and coverage from the editorial archive.
Bright Minds Bio
An interview with Gideon Shapiro, Co-Founder & VP of Discovery at Bright Minds Biosciences, where we discuss recent and upcoming events in psychedelic drug…
NervGen Pharma
NervGen is not an investment for the faint of heart, but for those investors who like to bet on trailblazing biotech companies with truly…
Sept 6, 2021
We generally don’t focus on the macro when writing our updates, but unfortunately, we can’t dive into company-specific updates without spending a minute on…
Virtual 1×1 Webinar with Epigenomics AG (ECX.DE, EPGNF)
Virtual 1×1 Webinar with Epigenomics AG (ECX.DE, EPGNF) Listen
Key Opinion Leader Conference Call with Dr. Jonathan Zager, Principal Investigator for Delcath System’s Phase 3 FOCUS Study
Key Opinion Leader Conference Call with Dr. Jonathan Zager, Principal Investigator for Delcath System’s Phase 3 FOCUS Study. Listen Download the transcript
Essa Pharma
We believe Big Pharma’s familiarity with AR antagonism makes Essa a legitimate M&A candidate. Read More.
Modular Medical
As the company “Pivots” from development to commercial stage, we believe shareholders could reap outsized returns. Read More.
March 7, 2021 Update
We thought it timely to provide an update on our coverage universe. Many of our names have imminent catalysts that warrant investors’ attention. We…
Processa Pharma
We believe by 2023, Processa could have one, or more, programs in Ph3, warranting a substantial bump in valuation, which we estimate to be…